By Nancy Lapid July 14 (Reuters) - Potential signs of frailty in older adults taking Eli Lilly's GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a lar… [+5018 chars]
No comments yet. Be the first to comment!